Developer docs
API playgroundTry for free, no card

Search company profiles

UniPhar

Full company profile

uuid0003g4h

Namestring
UniPhar
Legal namestring
Uniphar Plc
Websiteurl
uniphar.ie
Company typeenum
Public
Founded yearint
1967
Descriptiontext

Uniphar plc is an Irish diversified healthcare services group listed on AIM and Euronext Growth (ticker: UPR), headquartered in Dublin and founded in 1967 by community pharmacists. The company operates three core divisions: Uniphar Medtech (exclusive medical device distribution across 21 European markets), Uniphar Pharma (global pharmaceutical sourcing, managed access programs, clinical trial supply, and commercialization services), and Supply Chain + Retail (Ireland's market-leading pharmaceutical wholesaler serving 280+ retail pharmacy partners and 445+ network pharmacies across four symbol groups: Allcare, Hickey's, McCauley, and Life). Uniphar also runs medical affairs services (BestMSLs Group, acquired 2021) and pharmacy dispensing software (TouchStore, acquired January 2026), and supplies GMP/GDP-compliant clinical trial materials from facilities in Lelystad (Netherlands) and Raleigh (North Carolina).

The company's technology stack centres on digital distribution platforms rather than software products: a B2B e-commerce platform (Magento-based, with intelligent search and self-service) showing 143% online revenue growth from 2016 to 2019, a validated Quality Management System with ISO 9001:2015 certification across 70% of the organisation, integrated clinical trial supply chain platforms for comparator sourcing and packaging, and bespoke managed access / named patient program portals. The technology is functional infrastructure supporting the distribution and services franchise rather than a distinct AI/software product surface.

Uniphar's business model combines low-margin wholesale distribution (transaction-based revenue from pharma and medtech product flows) with higher-margin services including managed access programs, clinical trial supply, medical affairs outsourcing, and recurring retail pharmacy brand support. Revenue is generated through quote-based B2B contracts, multi-year manufacturer agreements (serving all top 10 global pharma companies and 7 of the top 10 medtech companies), and a network of channel partners across Europe, North America, APAC, and MENA. FY2025 revenue reached €3.1 billion (~11% YoY growth) with €457.7m gross profit and €130.9m EBITDA (~4.2% margin), and the group employs 3,589 people across Ireland, the UK, Benelux, the Nordics, and the United States.

Short descriptiontext

Uniphar plc is an Irish diversified healthcare services group operating pharmaceutical and medical device distribution, clinical trial supply, managed access programs, and a retail pharmacy network, serving 200+ manufacturers and 160+ countries across Europe, North America, APAC, and MENA.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersDublin, Ireland
HQ citystring
Dublin
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical distribution, medical device distribution, clinical trial supply, managed access programs, retail pharmacy services
Industry2 codes
PRIMARYCRAOAHAK
Pharmacy Benefit/Channel Services (PSAO, 340B Admin, Chargebacks/Rebates Ops)
SECONDARYHLAFALAA
Retail & Community Pharmacies (Chain/Independent)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
NAICS code2 codes
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
  • Pharmacies and Drug Retailers456110
SIC code2 codes
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Retail-Drug Stores And Proprietary Stores5912
Product category
Pharmaceutical and Healthcare Distribution Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharma & Medtech Distribution
TypeTransaction Fee
Description

Revenue generated from distributing pharmaceutical products and medical devices to pharmacies and hospitals across Ireland, Europe, and globally. Includes pre-wholesale and wholesale distribution services, as well as commercial and clinical services to pharma manufacturers.

uniphar.ie
2Retail Pharmacy Services
TypeSubscription Recurring
Description

Revenue from four pharmacy symbol groups (Allcare, Hickey's, McCauley, Life) providing buying power, category management, and support services to 280+ independent pharmacy partners in Ireland.

uniphar.ie
3Product Access & Clinical Services
TypeProfessional Services
Description

Global sourcing of unlicensed medicines, expanded access programs, clinical trial supply services, and pharma services provided to pharmaceutical and biotech manufacturers. Includes revenue from digital medical education platforms.

uniphar.ie
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details1 tier
1B2B distribution and services — no public pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based pricing for pharmaceutical distribution, clinical services, and pharmacy services. No public pricing information available.

uniphar.ie
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 7 records shown
1Allcare Pharmacy Group
Description

Pharmacy retail brand operating across Ireland.

uniphar.ie
+6 more records
Core offering1 text field

UniPhar is a diversified healthcare services group distributing pharmaceutical products and medical devices across Europe, North America, APAC, and MENA. The company operates three core divisions: Uniphar Medtech (exclusive medical device distribution across 21 European markets), Uniphar Pharma (clinical trial supply, expanded access programs, and global pharma services), and Supply Chain + Retail (Irish wholesale pharmaceutical distribution and a network of 445+ retail pharmacies operating under the Allcare, Hickey's, McCauley, and Life brands).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 143% online revenue growth from 2016 to 2019 through B2B e-commerce platform adoption
+6 more records
Product overview1 text field

UniPhar is a diversified healthcare solutions company operating across three main divisions: Uniphar Medtech (medical device distribution across 21 markets), Uniphar Pharma (global pharmaceutical sourcing, product access, and commercialization services), and Supply Chain + Retail (wholesale distribution and retail pharmacy brands). The company operates retail pharmacy brands including Allcare Pharmacy Group, Hickey's Pharmacy, and McCauley Health & Beauty. UniPhar's business model centers on pharmaceutical and medical device distribution, supply chain management, and retail pharmacy operations rather than a software-as-a-platform architecture. The company has made multiple acquisitions including BModesto Group, McCauley Pharmacy Group, Durbin, PharmaSource, BestMSLs Group, and others to build out its healthcare distribution and services portfolio. As a pharmaceutical/healthcare distribution and retail company, UniPhar's offerings are product-based (pharmaceuticals, medical devices) and service-based (distribution, clinical services) rather than software products with modules.

Product and service2 records
1Uniphar Medtech
CategoryMedical Device Distribution
Description

Exclusive distribution and commercial services for medical device manufacturers across 21 European markets. The service covers cardiology, orthopaedics, ophthalmology, and other specialties, leveraging field sales teams and regulatory expertise to support market access for medtech manufacturers.

2Uniphar Pharma
Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-23
Description

Uniphar joined the Orphan ClinDevNet network alongside OPIS, SK pharmteco, and TMC Pharma as a strategic partner providing clinical trial execution and UK/European regulatory and market access expertise. The network aims to overcome barriers that cause ultra-rare disease therapies to stall by providing a decentralized, outsourced infrastructure for development and commercialization.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-23
Description

Network partners in Orphan ClinDevNet alongside Uniphar, providing expanded access programs, U.S.-based viral vector manufacturing, and UK/European regulatory and market access expertise for ultra-rare disease therapies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-18
Description

Joint management of global Phase III trial for nanvuranlat (JPH203) for second-line biliary tract cancer following alignment with the US FDA on the regulatory pathway. Uniphar Development (Uniphar's regulatory and clinical development division) jointly manages the pivotal study with J-Pharma, allowing the drug to proceed directly to Phase III without an additional Phase II trial. First patients already randomized.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-26
Description

Strategic merger between Uniphar | Clinical and BMclinical forming a unified global partner for clinical trial supply. The combined entity integrates comparator sourcing expertise with integrated logistics services including sourcing, packaging, labeling, storage, and distribution of clinical materials. Facilities in Lelystad (Netherlands) and Raleigh (North Carolina) serve Europe, North America, APAC, and MENA. Merger aims to streamline global supply chains and improve reliability for pharma and biotech partners.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-12
Description

Exclusive distribution agreement for LYMPHIR (denileukin diftitox-cxdl) across designated Western and Eastern European territories through country-specific managed access programs. Uniphar handles market access and distribution activities while Citius Oncology supplies finished product. This marks Citius Oncology's third international distribution partnership, building on existing arrangements covering Southern Europe, the Balkans, Turkey, and the Middle East.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-29
Description

Exclusive distribution agreement for MIPLYFFA (arimoclomol) for the treatment of Niemann-Pick Disease Type C (NPC) outside of Europe. The agreement supports patient access expansion and complements Zevra's US and EU regulatory strategies. MIPLYFFA is FDA approved and under review by the EMA.

7European Accessibility Act Compliance
Strategic tierMinorTypeOthers
Description

Uniphar is committed to making its website accessible in accordance with the European Accessibility Act (Directive 2019/882), aligning with WCAG 2.1 level AA guidelines.

uniphar.ie
8Top 10 Global Pharma Companies (all served)
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Longstanding distribution and service relationships with all of the world's top 10 pharmaceutical companies, providing supply chain, commercial, and clinical services across multiple geographies.

uniphar.ie
9Top 10 Medical Device Companies (7 of top 10 served)
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive distribution agreements with some of the world's leading medical device manufacturers across 21 European markets for interventional cardiology, orthopaedics, ophthalmology, and other medical specialties.

uniphar.ie
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Web accessibility consultancy engaged to conduct self-assessment of web pages using WAVE (Web Accessibility Evaluation Tool) and VoiceOver screenreader for European Accessibility Act compliance.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Celesio / McKesson Europe
TypeDirect peer
Description

One of Europe's largest pharmaceutical wholesalers and retail pharmacy operators, owned by McKesson. UniPhar CEO Ger Rabbette was previously Managing Director of Celesio's Movianto, making this the closest direct comparable in pharma wholesale and patient access services.

TypeDirect peer
Description

European pharmaceutical wholesale and retail pharmacy group headquartered in Germany. Operates across multiple countries with both wholesale distribution and pharmacy retail banners — directly analogous to UniPhar's dual wholesale + retail pharmacy model in Ireland.

3Alliance Healthcare (Walgreens Boots Alliance)
TypeDirect peer
Description

Wholesale distributor of pharmaceuticals and consumer healthcare products across Europe, owned by Walgreens Boots Alliance. Closely comparable to UniPhar Pharma's pre-wholesale, wholesale, and patient access distribution in European markets.

4McKesson Corporation
TypeBroad incumbent
Description

Global pharmaceutical distribution and healthcare services leader with North America Pharma Solutions and McKesson Europe. Comparable in pharma wholesale and specialty services, but operating at materially greater scale and geographic breadth than UniPhar.

TypeBroad incumbent
Description

Top-tier US-based global pharmaceutical distributor with strong specialty distribution and consulting businesses (including PharmaLex and World Courier). Overlaps with UniPhar's pharma distribution, managed access, and clinical trial supply verticals at vastly larger scale.

TypeBroad incumbent
Description

Global pharmacy-led health and beauty retailer with both US retail pharmacy and European wholesale (Alliance Healthcare). Comparable to UniPhar's combination of Irish retail pharmacy brands (Allcare, Hickey's, Life, McCauley) and pharmaceutical distribution, although operating globally.

TypeDirect peer
Description

Global clinical research, commercial, and clinical trial supply services provider serving pharma and biotech manufacturers. Closely comparable to UniPhar's clinical trial supply, managed access, and outsourced medical affairs (BestMSLs) capabilities serving the same enterprise customer base.

TypeDirect peer
Description

Global contract development and manufacturing organization with strong clinical trial supply, packaging, and distribution capabilities. Closely comparable to UniPhar's combined BMclinical / Uniphar | Clinical platform for comparator sourcing, GMP/GDP-compliant trial materials supply across Europe and North America.

TypeBroad incumbent
Description

US-based global pharmaceutical and medical product distributor with both pharma distribution and at-Home Solutions / medical segments. Overlaps with UniPhar's combined pharmaceutical and medical device distribution model, though at much greater scale and with primary US exposure.

TypeBroad incumbent
Description

Global distributor of medical, dental, and veterinary healthcare products serving office-based practitioners and ambulatory surgery centers. Comparable to UniPhar Medtech's exclusive medical device distribution across 21 European markets for cardiology, orthopaedics, and ophthalmology customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries13 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A13 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

UniPhar

Pharmaceutical and Healthcare Distribution Servicesuniphar.ie

Uniphar plc is an Irish diversified healthcare services group operating pharmaceutical and medical device distribution, clinical trial supply, managed access programs, and a retail pharmacy network, serving 200+ manufacturers and 160+ countries across Europe, North America, APAC, and MENA.

What UniPhar does

Uniphar plc is an Irish diversified healthcare services group listed on AIM and Euronext Growth (ticker: UPR), headquartered in Dublin and founded in 1967 by community pharmacists. The company operates three core divisions: Uniphar Medtech (exclusive medical device distribution across 21 European markets), Uniphar Pharma (global pharmaceutical sourcing, managed access programs, clinical trial supply, and commercialization services), and Supply Chain + Retail (Ireland's market-leading pharmaceutical wholesaler serving 280+ retail pharmacy partners and 445+ network pharmacies across four symbol groups: Allcare, Hickey's, McCauley, and Life). Uniphar also runs medical affairs services (BestMSLs Group, acquired 2021) and pharmacy dispensing software (TouchStore, acquired January 2026), and supplies GMP/GDP-compliant clinical trial materials from facilities in Lelystad (Netherlands) and Raleigh (North Carolina).

The company's technology stack centres on digital distribution platforms rather than software products: a B2B e-commerce platform (Magento-based, with intelligent search and self-service) showing 143% online revenue growth from 2016 to 2019, a validated Quality Management System with ISO 9001:2015 certification across 70% of the organisation, integrated clinical trial supply chain platforms for comparator sourcing and packaging, and bespoke managed access / named patient program portals. The technology is functional infrastructure supporting the distribution and services franchise rather than a distinct AI/software product surface.

Uniphar's business model combines low-margin wholesale distribution (transaction-based revenue from pharma and medtech product flows) with higher-margin services including managed access programs, clinical trial supply, medical affairs outsourcing, and recurring retail pharmacy brand support. Revenue is generated through quote-based B2B contracts, multi-year manufacturer agreements (serving all top 10 global pharma companies and 7 of the top 10 medtech companies), and a network of channel partners across Europe, North America, APAC, and MENA. FY2025 revenue reached €3.1 billion (~11% YoY growth) with €457.7m gross profit and €130.9m EBITDA (~4.2% margin), and the group employs 3,589 people across Ireland, the UK, Benelux, the Nordics, and the United States.

UniPhar firmographics

Firmographics
Name
UniPhar
Legal name
Uniphar Plc
Website
https://uniphar.ie
Company type
Public
Founded year
1967
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Uniphar plc is an Irish diversified healthcare services group operating pharmaceutical and medical device distribution, clinical trial supply, managed access programs, and a retail pharmacy network, serving 200+ manufacturers and 160+ countries across Europe, North America, APAC, and MENA.
Ownership category
akta.pro rank

UniPhar industry classification

Industry
Product category
Pharmaceutical and Healthcare Distribution Services
NAICS
Drugs and Druggists' Sundries Merchant Wholesalers (42421), Pharmacies and Drug Retailers (456110)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Retail-Drug Stores And Proprietary Stores (5912)
akta.pro industry
PRIMARYCRAOAHAK
Pharmacy Benefit/Channel Services (PSAO, 340B Admin, Chargebacks/Rebates Ops)
SECONDARYHLAFALAA
Retail & Community Pharmacies (Chain/Independent)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services

Keywords

  • Pharmaceutical distribution
  • Medical device distribution
  • Clinical trial supply
  • Managed access programs
  • Retail pharmacy services

Where UniPhar is headquartered

Location

Headquarters

HQ city
Dublin
HQ country
Ireland
HQ region
Europe

Offices6 records

Markets served

UniPhar business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Pharma & Medtech Distribution: Revenue generated from distributing pharmaceutical products and medical devices to pharmacies and hospitals across Ireland, Europe, and globally. Includes pre-wholesale and wholesale distribution services, as well as commercial and clinical services to pharma manufacturers.
  2. Retail Pharmacy Services: Revenue from four pharmacy symbol groups (Allcare, Hickey's, McCauley, Life) providing buying power, category management, and support services to 280+ independent pharmacy partners in Ireland.
  3. Product Access & Clinical Services: Global sourcing of unlicensed medicines, expanded access programs, clinical trial supply services, and pharma services provided to pharmaceutical and biotech manufacturers. Includes revenue from digital medical education platforms.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractB2B distribution and services — no public pricing

Go-to-market motion2 records

Distribution channels6 records

Marketing channels6 records

UniPhar product offering

Product offering

Core offering

UniPhar is a diversified healthcare services group distributing pharmaceutical products and medical devices across Europe, North America, APAC, and MENA. The company operates three core divisions: Uniphar Medtech (exclusive medical device distribution across 21 European markets), Uniphar Pharma (clinical trial supply, expanded access programs, and global pharma services), and Supply Chain + Retail (Irish wholesale pharmaceutical distribution and a network of 445+ retail pharmacies operating under the Allcare, Hickey's, McCauley, and Life brands).

Product overview

UniPhar is a diversified healthcare solutions company operating across three main divisions: Uniphar Medtech (medical device distribution across 21 markets), Uniphar Pharma (global pharmaceutical sourcing, product access, and commercialization services), and Supply Chain + Retail (wholesale distribution and retail pharmacy brands). The company operates retail pharmacy brands including Allcare Pharmacy Group, Hickey's Pharmacy, and McCauley Health & Beauty. UniPhar's business model centers on pharmaceutical and medical device distribution, supply chain management, and retail pharmacy operations rather than a software-as-a-platform architecture. The company has made multiple acquisitions including BModesto Group, McCauley Pharmacy Group, Durbin, PharmaSource, BestMSLs Group, and others to build out its healthcare distribution and services portfolio. As a pharmaceutical/healthcare distribution and retail company, UniPhar's offerings are product-based (pharmaceuticals, medical devices) and service-based (distribution, clinical services) rather than software products with modules.

Differentiator

Problem solved

Functional benefit

Brands

  • Allcare Pharmacy Group: Pharmacy retail brand operating across Ireland.
  • Hickey's Pharmacy Group
  • McCauley Health & Beauty
  • Life Pharmacy
  • Durbin
  • BestMSLs Group
  • BModesto Group

Products and services

  • Uniphar Medtech Exclusive distribution and commercial services for medical device manufacturers across 21 European markets. The service covers cardiology, orthopaedics, ophthalmology, and other specialties, leveraging field sales teams and regulatory expertise to support market access for medtech manufacturers.
  • Uniphar Pharma

Quantifiable outcome

  • 143% online revenue growth from 2016 to 2019 through B2B e-commerce platform adoption
  • +6 more outcomes

Companies that use UniPhar

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles4 records

UniPhar technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

UniPhar partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered minor and core.

  • Orphan Therapeutics Accelerator (OTXL)minorStrategic or Co-development Partner · 23 June 2026Uniphar joined the Orphan ClinDevNet network alongside OPIS, SK pharmteco, and TMC Pharma as a strategic partner providing clinical trial execution and UK/European regulatory and market access expertise. The network aims to overcome barriers that cause ultra-rare disease therapies to stall by providing a decentralized, outsourced infrastructure for development and commercialization.
  • OPIS (Organon), SK pharmteco, TMC PharmaminorStrategic or Co-development Partner · 23 June 2026Network partners in Orphan ClinDevNet alongside Uniphar, providing expanded access programs, U.S.-based viral vector manufacturing, and UK/European regulatory and market access expertise for ultra-rare disease therapies.
  • J-PharmacoreStrategic or Co-development Partner · 18 June 2026Joint management of global Phase III trial for nanvuranlat (JPH203) for second-line biliary tract cancer following alignment with the US FDA on the regulatory pathway. Uniphar Development (Uniphar's regulatory and clinical development division) jointly manages the pivotal study with J-Pharma, allowing the drug to proceed directly to Phase III without an additional Phase II trial. First patients already randomized.
  • BMclinicalcoreStrategic or Co-development Partner · 26 February 2026Strategic merger between Uniphar | Clinical and BMclinical forming a unified global partner for clinical trial supply. The combined entity integrates comparator sourcing expertise with integrated logistics services including sourcing, packaging, labeling, storage, and distribution of clinical materials. Facilities in Lelystad (Netherlands) and Raleigh (North Carolina) serve Europe, North America, APAC, and MENA. Merger aims to streamline global supply chains and improve reliability for pharma and biotech partners.
  • Citius OncologycoreChannel Partner/ Reseller/ Distributor · 12 February 2026Exclusive distribution agreement for LYMPHIR (denileukin diftitox-cxdl) across designated Western and Eastern European territories through country-specific managed access programs. Uniphar handles market access and distribution activities while Citius Oncology supplies finished product. This marks Citius Oncology's third international distribution partnership, building on existing arrangements covering Southern Europe, the Balkans, Turkey, and the Middle East.
  • Zevra TherapeuticscoreChannel Partner/ Reseller/ Distributor · 29 December 2025Exclusive distribution agreement for MIPLYFFA (arimoclomol) for the treatment of Niemann-Pick Disease Type C (NPC) outside of Europe. The agreement supports patient access expansion and complements Zevra's US and EU regulatory strategies. MIPLYFFA is FDA approved and under review by the EMA.
  • European Accessibility Act ComplianceminorOthersUniphar is committed to making its website accessible in accordance with the European Accessibility Act (Directive 2019/882), aligning with WCAG 2.1 level AA guidelines.
  • Top 10 Global Pharma Companies (all served)coreChannel Partner/ Reseller/ DistributorLongstanding distribution and service relationships with all of the world's top 10 pharmaceutical companies, providing supply chain, commercial, and clinical services across multiple geographies.
  • Top 10 Medical Device Companies (7 of top 10 served)coreChannel Partner/ Reseller/ DistributorExclusive distribution agreements with some of the world's leading medical device manufacturers across 21 European markets for interventional cardiology, orthopaedics, ophthalmology, and other medical specialties.
  • Monsoon ConsultingminorImplementation/ SI/ Consulting PartnerWeb accessibility consultancy engaged to conduct self-assessment of web pages using WAVE (Web Accessibility Evaluation Tool) and VoiceOver screenreader for European Accessibility Act compliance.

Scale indicators13 records

Recent moves6 records

Expansion highlights6 records

UniPhar competitors and assessment

Company assessment

Direct peers

  • Celesio / McKesson Europe: One of Europe's largest pharmaceutical wholesalers and retail pharmacy operators, owned by McKesson. UniPhar CEO Ger Rabbette was previously Managing Director of Celesio's Movianto, making this the closest direct comparable in pharma wholesale and patient access services.
  • Phoenix Group: European pharmaceutical wholesale and retail pharmacy group headquartered in Germany. Operates across multiple countries with both wholesale distribution and pharmacy retail banners — directly analogous to UniPhar's dual wholesale + retail pharmacy model in Ireland.
  • Alliance Healthcare (Walgreens Boots Alliance): Wholesale distributor of pharmaceuticals and consumer healthcare products across Europe, owned by Walgreens Boots Alliance. Closely comparable to UniPhar Pharma's pre-wholesale, wholesale, and patient access distribution in European markets.
  • IQVIA: Global clinical research, commercial, and clinical trial supply services provider serving pharma and biotech manufacturers. Closely comparable to UniPhar's clinical trial supply, managed access, and outsourced medical affairs (BestMSLs) capabilities serving the same enterprise customer base.
  • PCI Pharma Services: Global contract development and manufacturing organization with strong clinical trial supply, packaging, and distribution capabilities. Closely comparable to UniPhar's combined BMclinical / Uniphar | Clinical platform for comparator sourcing, GMP/GDP-compliant trial materials supply across Europe and North America.

Broad incumbents

  • McKesson Corporation: Global pharmaceutical distribution and healthcare services leader with North America Pharma Solutions and McKesson Europe. Comparable in pharma wholesale and specialty services, but operating at materially greater scale and geographic breadth than UniPhar.
  • Cencora (formerly AmerisourceBergen): Top-tier US-based global pharmaceutical distributor with strong specialty distribution and consulting businesses (including PharmaLex and World Courier). Overlaps with UniPhar's pharma distribution, managed access, and clinical trial supply verticals at vastly larger scale.
  • Walgreens Boots Alliance: Global pharmacy-led health and beauty retailer with both US retail pharmacy and European wholesale (Alliance Healthcare). Comparable to UniPhar's combination of Irish retail pharmacy brands (Allcare, Hickey's, Life, McCauley) and pharmaceutical distribution, although operating globally.
  • Cardinal Health: US-based global pharmaceutical and medical product distributor with both pharma distribution and at-Home Solutions / medical segments. Overlaps with UniPhar's combined pharmaceutical and medical device distribution model, though at much greater scale and with primary US exposure.
  • Henry Schein: Global distributor of medical, dental, and veterinary healthcare products serving office-based practitioners and ambulatory surgery centers. Comparable to UniPhar Medtech's exclusive medical device distribution across 21 European markets for cardiology, orthopaedics, and ophthalmology customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

UniPhar social profiles

Digital presence

UniPhar financial estimates

Financial estimate

Revenue estimate

Valuation estimate

UniPhar leadership team

Management profile

Number of profiles

Profiles13 records

UniPhar subsidiaries and ownership

Company hierarchy

Subsidiaries13 records

UniPhar funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

UniPhar M&A and investment

M&A and investment

M&A13 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about UniPhar

What does UniPhar do?

UniPhar is a diversified healthcare services group distributing pharmaceutical products and medical devices across Europe, North America, APAC, and MENA. The company operates three core divisions: Uniphar Medtech (exclusive medical device distribution across 21 European markets), Uniphar Pharma (clinical trial supply, expanded access programs, and global pharma services), and Supply Chain + Retail (Irish wholesale pharmaceutical distribution and a network of 445+ retail pharmacies operating under the Allcare, Hickey's, McCauley, and Life brands).

Is UniPhar a public or private company?

UniPhar is a public company. It is classified as public and is currently operating.

When was UniPhar founded?

UniPhar was founded in 1967. It employs 501 to 1,000 people.

Where is UniPhar based?

UniPhar is headquartered in Dublin, Ireland, in the Europe region.

How does UniPhar make money?

Three revenue lines are on record. Pharma & Medtech Distribution is the primary driver. The others are retail Pharmacy Services and product Access & Clinical Services.

Who are UniPhar's main competitors?

Direct peers on record are Celesio / McKesson Europe, Phoenix Group, Alliance Healthcare (Walgreens Boots Alliance), IQVIA and PCI Pharma Services. Broad incumbents are McKesson Corporation, Cencora (formerly AmerisourceBergen), Walgreens Boots Alliance, Cardinal Health and Henry Schein.

Does UniPhar have an API?

No public API is recorded for UniPhar.

What industry is UniPhar in?

UniPhar's product category is Pharmaceutical and Healthcare Distribution Services. Its primary akta.pro industry code is CRAOAHAK, Pharmacy Benefit/Channel Services (PSAO, 340B Admin, Chargebacks/Rebates Ops), with a secondary code of HLAFALAA, Retail & Community Pharmacies (Chain/Independent). Its NAICS code is 42421 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewREG - Uniphar PLC - Holding(s) in CompanyThreadneedle Asset Management Holdings Limited was notified on 11 November 2026 that it holds 9,838,730 ordinary shares in Uniphar plc, representing 3.79% of issued share capital. The stake was held as of 9 September 2026.Simply Wall StWhy Uniphar plc (ISE:UPR) Could Be Worth WatchingUniphar's shares rose over 10% in recent months, trading at a 21.04x PE ratio versus an industry average of 17.96x. Analysts expect earnings to grow 47% over the next few years, suggesting potential for further price drops. The stock's high beta indicates volatility, offering a chance to buy lower.YahooUniphar (ISE:UPR) Lifts Dividend And Backs Acquisitions On A Cheap Looking ValuationUniphar reported higher sales and net income for the half year, lifting its interim dividend and reiterating acquisition plans. The stock trades at a discount to analyst targets, with fair value estimated at €5.34. Execution of its expansion plans and capital deployment will determine whether the undervaluation holds.Simply Wall StUniphar (ISE:UPR) Could Be 25% Below Fair Value As Profit And Dividend RiseUniphar reported higher half-year sales and net income, raising its interim dividend by 4.2% while its share price fell 6.8% over 30 days. The stock trades at €4.00, below a fair value estimate of €5.34, with a P/E of 19.4x. The company's M&A pipeline and buyback plans may support further value creation.Simply Wall StUniphar (ISE:UPR) Stock Can Revenue Growth Outrun Cash Flow Strain?Uniphar reported H1 2026 revenue of €1,591.855m, up 7.2% year-over-year, with adjusted EPS of €0.109. However, free cash flow turned negative at €47m, and leverage reached 2.4x net debt to EBITDA. Management reiterated a €200m EBITDA target for 2028 and a 60-70% free cash flow conversion goal.Irish ExaminerUniphar reports 8.6% growth in operating profitUniphar's operating profit rose 8.6% to €35.4m in the first half of the year, with revenue up 7.2% to €1.59bn. Gross profit increased 7.7% to just under €236.5m, and the company said it is on track to meet growth objectives.The Irish TimesUniphar profit continues to grow in first half of 2026Uniphar reported growing profit in the first half of 2026, with gross profit rising 7.7% and revenue exceeding €370 million. Adjusted EPS grew 11.2% to 10.9 cents, and the board declared an interim dividend of €0.0074 per share. The company expects to sustain progress into the second half and meet its 2028 ebitda target.Irish ExaminerCompetition watchdog probes Uniphar deal to acquire Limerick's TouchstoreThe competition watchdog will conduct a full investigation into Uniphar's planned acquisition of Limerick pharmacy software firm TouchStore, announced in January. Uniphar is one of two full-line pharmaceutical wholesalers in Ireland and also owns retail stores, franchise networks, and buying groups.The Irish TimesUniphar reports strong half-year performanceIrish healthcare services group Uniphar reported strong first-half 2025 performance with 11% adjusted EPS growth and approximately 7% organic gross profit growth across all three divisions. The company confirmed it remains on track to reach its €200 million EBITDA target by 2028, with at least 80% of growth expected to be organic. A new high-tech distribution facility in Ireland has been delayed to February 2027, requiring an additional €20 million in capital expenditure.AijournOrphan Therapeutics Accelerator Expands its Network to Extend Development and Access Pathways for Ultra-Rare Disease TherapiesOrphan Therapeutics Accelerator (OTXL) announced the expansion of its development network, Orphan ClinDevNet, through the addition of four strategic partners: OPIS, Uniphar, SK pharmteco, and TMC Pharma. The new partners add targeted capabilities across clinical trial execution, expanded access programs, U.S.-based viral vector manufacturing, and UK/European regulatory and market access expertise. This expansion aims to help overcome barriers that cause ultra-rare disease therapies to stall, by providing a decentralized, outsourced infrastructure for development and commercialization.